Cargando…

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes

Insulin icodec is a once-weekly basal insulin analogue in late-phase clinical development. Similar efficacy and safety of icodec to once-daily basal insulin analogues have been reported in over 4,200 participants with type 2 diabetes from three phase II and five phase III trials. Indeed, glycated ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bajaj, Harpreet S, Goldenberg, Ronald M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Touch Medical Media 2023
Materias:	Diabetes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258611/ https://www.ncbi.nlm.nih.gov/pubmed/37313230 http://dx.doi.org/10.17925/EE.2023.19.1.4

Ejemplares similares

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
por: Bajaj, Harpreet S., et al.
Publicado: (2021)

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing
por: Nishimura, Erica, et al.
Publicado: (2021)

Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2022)

LBSUN210 Efficacy And Safety Profile Of Insulin Icodec Versus Insulin Glargine U100 In Type 2 Diabetes Mellitus: A Meta-Analysis Of Randomized Controlled Trials
por: Dimayuga, Diana Colleen, et al.
Publicado: (2022)

Abstract 141: CGM-based measurements for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-treated patients with type 2 diabetes: A post hoc analysis
por: Chandrappa, Manu, et al.
Publicado: (2022)

Combination Therapy With Premixed & Basal Insulin Analogues in Asian Indians With Type 2 Diabetes
por: Srivastava, Brijendra Kumar, et al.
Publicado: (2021)

Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

Once Weekly Basal Insulin Fc (BIF) is Safe and Efficacious in Patients with Type 2 Diabetes Mellitus (T2DM) Previously Treated With Basal Insulin
por: Frias, Juan Pablo, et al.
Publicado: (2021)

Abstract 5: Similar hypoglycemia duration with once-weekly insulin icodec versus insulin glargine U100 in insulin naïve or experienced patients with T2D
por: Manjunath, Aparna, et al.
Publicado: (2022)

Abstract 3: CGM-derived parameters for once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-Naïve patients with T2D
por: Kunder, Sushil, et al.
Publicado: (2022)

Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials
por: Silva, Rodrigo Ribeiro e, et al.
Publicado: (2023)

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Preclinical Characterization of Once Weekly Basal Insulin Fc (BIF)
por: Moyers, Julie S, et al.
Publicado: (2021)

Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

Expectations about and experiences with insulin therapy contribute to diabetes treatment satisfaction in insulin-naïve patients with type 2 diabetes
por: Naegeli, A N, et al.
Publicado: (2010)

A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study
por: Ito, Hiroyuki, et al.
Publicado: (2018)

Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial
por: Pieber, Thomas R., et al.
Publicado: (2023)

Insulin Matters: A Practical Approach to Basal Insulin Management in Type 2 Diabetes
por: Berard, Lori, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus
por: Plum-Mörschel, Leona, et al.
Publicado: (2023)

Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis
por: Freemantle, Nick, et al.
Publicado: (2016)

An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes
por: Lingvay, Ildiko, et al.
Publicado: (2022)

Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond
por: Bretzel, Reinhard G., et al.
Publicado: (2009)

PSUN181 Diabetes-related outcomes following use of basal-bolus insulin vs. premixed insulin in a VA population with Type 2 diabetes: A retrospective chart review.
por: Izuora, Kenneth, et al.
Publicado: (2022)

Basal Insulin Inadequacy versus Failure – Using Appropriate Terminology
por: Kalra, Sanjay, et al.
Publicado: (2015)

Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
por: Lim, Beng Leong, et al.
Publicado: (2023)

The metabolic and mitogenic properties of basal insulin analogues
por: Tennagels, Norbert, et al.
Publicado: (2013)

Reconsidering the Basal Proportion of Insulin Dose: Glycemic and Microvascular Outcomes in Type 1 Diabetes Mellitus
por: Pozos-Varela, Francisco Javier, et al.
Publicado: (2021)

Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes
por: Nallicheri, Armaan, et al.
Publicado: (2022)

Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes
por: Bolli, Geremia B., et al.
Publicado: (2011)

FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US
por: Hoog, Meredith, et al.
Publicado: (2023)

Comparison of Human Premixed and Basal Plus Short-Acting Insulin Regimens for Individuals With Type 2 Diabetes During Ramadan Fasting
por: Altemimi, Mahmood Thamer, et al.
Publicado: (2020)

Insulin Therapy for Type 2 Diabetes
por: Swinnen, Sanne G., et al.
Publicado: (2009)

PSUN278 Factitious hypoglycemia, diagnostic delay due to insulin assay failure to detect insulin analogues.
por: Harned, Leighton Kahle, et al.
Publicado: (2022)

FRI642 The Effect Of Early Basal Insulin Administration On Diabetic Ketoacidosis (DKA) Management
por: Al-Marsumi, Hadeel, et al.
Publicado: (2023)

Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus
por: Choe, Eun Yeong, et al.
Publicado: (2012)

Impact of Pocket Insulin Dosing Guide on Utilization of Basal/Bolus Insulin by Internal Medicine Resident Physicians
por: Mamillapalli, Chaitanya K, et al.
Publicado: (2018)

Recombinant Human Insulins – Clinical Efficacy and Safety in Diabetes Therapy
por: Landgraf, Wolfgang, et al.
Publicado: (2016)

‘Is Insulin Right for Me?’ Development of a theory-informed, web-based resource for reducing psychological barriers to insulin therapy in type 2 diabetes
por: Holloway, Edith E, et al.
Publicado: (2021)

Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial
por: Hramiak, Irene, et al.
Publicado: (2022)

The Clinical Impact of Switching Basal Insulin to Insulin Degludec in Patients With Diabetes in Saudi Arabia: A Retrospective One-Group Pretest-Posttest Design Study
por: Althagafi, Abdulhamid, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_067vas36tukto2v3cckqv7liqi